Display options
Cite
Schmidt E, Zillikens D. Diagnosis and clinical severity markers of bullous pemphigoid. F1000 Med Rep. 2009;1doi: 10.3410/M1-15.
Schmidt, E., & Zillikens, D. (2009). Diagnosis and clinical severity markers of bullous pemphigoid. F1000 medicine reports, 1. https://doi.org/10.3410/M1-15
Schmidt, Enno, and Zillikens, Detlef. "Diagnosis and clinical severity markers of bullous pemphigoid." F1000 medicine reports vol. 1 (2009). doi: https://doi.org/10.3410/M1-15
Schmidt E, Zillikens D. Diagnosis and clinical severity markers of bullous pemphigoid. F1000 Med Rep. 2009 Feb 24;1. doi: 10.3410/M1-15. PMID: 20948767; PMCID: PMC2920699.
Copy Download .nbib Format: NLM
Share it on

F1000 Med Rep. 2009 Feb 24;1. doi: 10.3410/M1-15.

Diagnosis and clinical severity markers of bullous pemphigoid.

F1000 medicine reports

Enno Schmidt, Detlef Zillikens

Affiliations

  1. Department of Dermatology, University of Lübeck Ratzeburger Allee 160, D-23538 Lübeck Germany.

PMID: 20948767 PMCID: PMC2920699 DOI: 10.3410/M1-15

Abstract

The use of a broad spectrum of novel detection systems for autoantibodies to the basement membrane proteins BP180 and BP230 has greatly facilitated the diagnosis of bullous pemphigoid, which most likely explains its increasing incidence in central Europe. Because the pathogenic relevance of antibodies to human BP180 has been convincingly shown both in vitro and in vivo, repeated testing for these antibodies appears to be helpful in guiding treatment decisions during the course of the disease.

References

  1. Ann N Y Acad Sci. 2005 Jun;1051:104-10 - PubMed
  2. Int J Dermatol. 2006 Sep;45(9):1047-52 - PubMed
  3. J Invest Dermatol. 2004 Jun;122(6):1413-22 - PubMed
  4. Nat Med. 2007 Mar;13(3):378-83 - PubMed
  5. Int J Dermatol. 2008 Mar;47(3):225-8 - PubMed
  6. J Dermatol. 2004 May;31(5):383-91 - PubMed
  7. J Dermatol Sci. 2001 May;26(1):14-8 - PubMed
  8. J Dermatol Sci. 2006 Jan;41(1):21-30 - PubMed
  9. J Dermatol Sci. 2008 Feb;49(2):153-61 - PubMed
  10. J Immunol. 1986 Feb 15;136(4):1231-5 - PubMed
  11. J Invest Dermatol. 2008 Nov;128(11):2736-2739 - PubMed
  12. Br J Dermatol. 2004 Nov;151(5):1004-10 - PubMed
  13. Arch Dermatol. 2008 Jan;144(1):41-8 - PubMed
  14. J Invest Dermatol. 2002 Nov;119(5):1065-73 - PubMed
  15. J Invest Dermatol. 2000 May;114(5):998-1004 - PubMed
  16. Br J Dermatol. 2009 Feb;160(2):429-32 - PubMed
  17. Br J Dermatol. 2001 Dec;145(6):998-1004 - PubMed
  18. J Invest Dermatol. 2009 Apr;129(4):919-26 - PubMed
  19. J Invest Dermatol. 2007 May;127(5):1167-74 - PubMed
  20. J Dermatol Sci. 2005 Mar;37(3):145-9 - PubMed
  21. J Dermatol Sci. 2002 Dec;30(3):224-32 - PubMed
  22. BMJ. 2008 Aug 06;337:a1138 - PubMed
  23. Exp Dermatol. 2007 Sep;16(9):770-7 - PubMed
  24. J Am Acad Dermatol. 2000 Apr;42(4):577-83 - PubMed
  25. J Invest Dermatol. 2007 Nov;127(11):2605-11 - PubMed
  26. Ann Dermatol Venereol. 2006 May;133(5 Pt 1):439-43 - PubMed
  27. J Invest Dermatol. 2000 Nov;115(5):842-8 - PubMed
  28. J Invest Dermatol. 1997 Oct;109(4):573-9 - PubMed
  29. J Invest Dermatol. 2004 Jan;122(1):103-10 - PubMed
  30. Clin Immunol. 2008 Sep;128(3):415-26 - PubMed
  31. J Invest Dermatol. 1999 Feb;112(2):141-7 - PubMed
  32. Arch Dermatol. 2000 Feb;136(2):174-8 - PubMed
  33. J Dtsch Dermatol Ges. 2009 May;7(5):434-40 - PubMed
  34. Cell. 1981 Jun;24(3):897-903 - PubMed
  35. Eur J Immunol. 2006 Apr;36(4):1039-48 - PubMed
  36. BMJ. 2008 Jul 09;337:a180 - PubMed
  37. Exp Dermatol. 2001 Aug;10(4):256-63 - PubMed
  38. J Autoimmun. 2000 Nov;15(3):293-300 - PubMed
  39. J Am Acad Dermatol. 2008 Jun;58(6):951-8 - PubMed
  40. J Invest Dermatol. 2005 Sep;125(3):467-72 - PubMed
  41. Eur J Dermatol. 2008 Sep-Oct;18(5):534-8 - PubMed
  42. J Invest Dermatol. 2005 Apr;124(4):732-40 - PubMed
  43. Clin Immunol. 2004 Apr;111(1):146-52 - PubMed
  44. Arch Dermatol. 1995 Aug;131(8):957-8 - PubMed

Publication Types